

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with conventional disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only (review of technology appraisal guidance 130, 186, 224, 234 and a part review of technology appraisal guidance 225 and 247)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No issues were identified, except to note that rheumatoid arthritis is a leading cause of disability, and more effective treatments for the condition would reduce discrimination and promote equity.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No actions would be required.

Technology appraisals: Scoping

Equality impact assessment for the proposed multiple technology appraisal of Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with conventional disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only (review of technology appraisal guidance 130, 186, 224, 234 and a part review of technology appraisal guidance 225 and 247)

Issue date: November 2012

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name): Frances Sutcliffe

Date: 6 November 2012

Technology appraisals: Scoping

Equality impact assessment for the proposed multiple technology appraisal of Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with conventional disease-modifying anti-rheumatic drugs and

after the failure of conventional disease-modifying anti-rheumatic drugs only (review of technology appraisal guidance 130, 186, 224, 234 and a part review of technology appraisal guidance 225 and 247)

Issue date: November 2012